Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
J Transl Med. 2024 Sep 2;22(1):813. doi: 10.1186/s12967-024-05539-3.
Inflammatory bowel disease (IBD) represents a group of recurrent chronic inflammatory disorders associated with autoimmune dysregulation, typically characterized by neutrophil infiltration and mucosal inflammatory lesions. Neutrophils, as the earliest immune cells to arrive at inflamed tissues, play a dual role in the onset and progression of mucosal inflammation in IBD. Most of these cells specifically express CD177, a molecule increasingly recognized for its critical role in the pathogenesis of IBD. Under IBD-related inflammatory stimuli, CD177 is highly expressed on neutrophils and promotes their migration. CD177 + neutrophils activate bactericidal and barrier-protective functions at IBD mucosal inflammation sites and regulate the release of inflammatory mediators highly correlated with the severity of inflammation in IBD patients, thus playing a dual role. However, mitigating the detrimental effects of neutrophils in inflammatory bowel disease remains a challenge. Based on these data, we have summarized recent articles on the role of neutrophils in intestinal inflammation, with a particular emphasis on CD177, which mediates the recruitment, transepithelial migration, and activation of neutrophils, as well as their functional consequences. A better understanding of CD177 + neutrophils may contribute to the development of novel therapeutic targets to selectively modulate the protective role of this class of cells in IBD.
炎症性肠病（IBD）是一组反复发作的慢性炎症性疾病，与自身免疫失调有关，通常表现为中性粒细胞浸润和黏膜炎症病变。中性粒细胞作为最早到达炎症组织的免疫细胞，在 IBD 黏膜炎症的发生和进展中发挥双重作用。这些细胞大多数特异性表达 CD177，该分子在 IBD 的发病机制中具有关键作用，越来越受到重视。在与 IBD 相关的炎症刺激下，CD177 在中性粒细胞上高度表达，促进其迁移。CD177+中性粒细胞在 IBD 黏膜炎症部位发挥杀菌和屏障保护功能，并调节与 IBD 患者炎症严重程度高度相关的炎症介质的释放，从而发挥双重作用。然而，减轻炎症性肠病中性粒细胞的有害影响仍然是一个挑战。基于这些数据，我们总结了最近关于中性粒细胞在肠道炎症中的作用的文章，特别强调了 CD177，它介导中性粒细胞的募集、跨上皮迁移和激活及其功能后果。更好地了解 CD177+中性粒细胞可能有助于开发新的治疗靶点，以选择性调节这类细胞在 IBD 中的保护作用。
